Antihypertensive Drugs Market Share Analysis Report, 2022-2030
The global Antihypertensive Drugs market size was estimated at USD 30.8 billion in 2021 and is expected to surpass around USD 41 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 3.45% during the forecast period 2022 to 2030.
Overview of Antihypertensive Drugs Market
Antihypertensive medications are used to treat high blood pressure. Different types of antihypertensive drugs are available in the market. These help lower blood pressure. Some remove excess fluid and salt from the body, while others help relax and widen blood vessels or slow the heart rate. A person could respond better and experience fewer side effects to one drug than to another. Some patients require more than one antihypertensive agent to lower blood pressure.
Hypertension is a preventable risk factor for atherosclerotic disease and ischemic heart disease. A number of patients maintain suboptimal blood pressure control despite the availability of modern and effective antihypertensive drugs. Most hypertensive patients require a combination of antihypertensive agents to achieve treatment goals. Under combination therapy, another class of blood pressure medication is added to the first drug to increase its effectiveness. The antihypertensive drugs market has reasonably high unmet demand, which indicates the lack of effective products. This presents significant opportunities for new entrants to capitalize on the unmet needs, largely due to poor patient compliance with products currently available in the market.
Trends in antihypertensive medication in stroke survivors could provide important insights into gaps in secondary prevention that can guide improved interventions in the future. Healthcare companies are increasing R&D in the field of genomics and resistant hypertension treatment to gain a competitive edge over other market players.
Report Scope of the Antihypertensive Drugs Market
|
Report Coverage |
Details |
|
Market Size |
USD 41 Billion by 2030 |
|
Growth Rate |
CAGR of 3.45% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Therapy Type, Type, Medication Type, Distribution Channel And Geography, |
|
Companies Mentioned |
|
Launch of New Disease-modifying Therapies to Drive Global Antihypertensive Drugs Market
Innovative antihypertensive drugs and drug therapies are expected to offer favorable outcomes, as these effectively target disease progression. The current scenario in the global antihypertensive drugs market is expected to change due to the launch of new therapies for diseases such as angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, and calcium channel blockers (CCB) during the forecast period.
Currently, physicians prescribe fewer diuretics and beta-blockers, common first-line agents for hypertension, and more ACE and CHF inhibitors. ACE inhibitors reduce mortality and morbidity in cardiovascular patients; however, this is not true for CCBs. If control is not available on beta-blockers, diuretics, or ACE inhibitors, short-acting CHFs should be avoided and alternatives should be considered. Unlike ACE inhibitors, ARBs do not cause cough. Therefore, launch of innovative drug/therapeutic molecules with disease-modifying properties and improved efficacy and safety is expected to drive the global antihypertensive drugs market in the next few years.
Promising Products in Pipeline to Boost Demand for Antihypertensive Drugs
Treatments for hypertension are relatively potent. Several drugs are being studied in clinical trials, including those with disease-modifying properties, better safety, and effectiveness, which can reduce disease progression significantly.
Launch of new products with improved efficiency and safety is expected to drive the market. Bayer's candesartan cilexetil/nifedipine (phase III), Boryung Pharmaceuticals' fimasartan/amlodipine (phase III), and Takeda Pharmaceuticals' diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) are some of the drugs under development.
Companies Establish Stable Revenue Streams by Augmenting Production of Angiotensin Receptor Blockers
In terms of therapy type, the global antihypertensive drugs market has been classified into diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, vasodilators, calcium channel blockers, renin inhibitors, alpha-blockers, and others. The angiotensin receptor blockers segment is projected to dominate the global market during the forecast period. The segment is expected to grow at a high CAGR from 2021 to 2030. Angiotensin II receptor blockers (ARBs) have a similar effect to ACE inhibitors, another type of blood pressure drug, but work on a different mechanism.
High Salt Intake to Propel Demand for Antihypertensive Drugs for Primary Hypertension Management
Based on type, the global antihypertensive drugs market has been bifurcated into primary hypertension and secondary hypertension. The primary hypertension segment is projected to dominate the global market during the forecast period. The segment is anticipated to grow at a high CAGR from 2022 to 2030. Hypertension has become a global health concern over the last decade. In the developed world, salt intake is generally above the recommended quantity among children. Similar trend exists in the developing world. Positive sodium balance is needed for growth in the first year of life; however, high salt intake could have harmful cardiovascular consequences.
Increase in Geriatric Population with Comorbidities Driving Need for Combination Therapy
In terms of medication, the global antihypertensive drugs market has been segregated into monotherapy, combination therapy, and fixed dose combinations. The combination therapy segment is projected to dominate the market, with significant revenue share by 2030. The segment is anticipated to advance at a high CAGR from 2022 to 2030. Rise in geriatric population with comorbid conditions such as congenital heart disease; and focus on combination therapies are driving the combination therapy segment. Thus, manufacturers are increasing the production of combination antihypertensive drugs to meet the needs of elderly patients with comorbidities.
Broad Medicine Portfolio to Boost Hospital Pharmacies Segment
Based on distribution channel, the global antihypertensive drugs market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment dominated the global market in 2021. Hospital pharmacies usually stock a wide range of medicines, including specialized and investigational medications. Hospital pharmacies are increasing the availability of hypertension management devices to broaden their income sources.
Regional Outlook of Global Antihypertensive Drugs Market
North America dominated the global antihypertensive drugs market in 2021. The market in the region is projected to grow at a high CAGR from 2022 to 2030. North America is anticipated to sustain its market share during the forecast period. High adoption of antihypertensive drugs in the U.S., increase in the number of approvals for new drugs by the U.S. FDA, and rise in percentage of people suffering from cardiovascular diseases in the U.S. and Canada contribute to North America's significant market share.
The market in Asia Pacific region is expected to grow at a high CAGR during the forecast period, owing to the large patient pool, increase in incidence of heart diseases, aging population, and high demand and export of drugs to Europe and North America.
Analysis of Key Players in Antihypertensive Drugs Market
The global antihypertensive drugs market is consolidated, with a small number of leading players accounting for major share. Large numbers of companies are investing in research & development activities. Diversification of product portfolios and mergers & acquisitions are important strategies adopted by key players. Pfizer, Inc., Sanofi S.A, Novartis AG, Boehringer Ingelheim GmbH, Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited are the prominent players operating in the global market.
Key Developments in Global Antihypertensive Drugs Market
Some of the prominent players in the Antihypertensive Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antihypertensive Drugs market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Antihypertensive Drugs Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Bn)
5. Market Outlook
5.1. Key Industry Developments
5.2. Impact scenario
5.3. New product developments
6. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Global Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017–2030
6.2.1. Diuretics
6.2.1.1. Thiazide diuretics
6.2.1.2. Loop diuretics
6.2.1.3. Potassium-sparing diuretics
6.2.2. Angiotensin Converting Enzyme Inhibitors
6.2.3. Angiotensin Receptor Blockers
6.2.4. Beta-blockers
6.2.4.1. Beta-1 Selective
6.2.4.2. Intrinsic Sympathomimetic
6.2.5. Vasodilators
6.2.6. Calcium Channel Blockers
6.2.7. Renin Inhibitors
6.2.8. Alpha-blockers
6.2.9. Others
6.3. Global Antihypertensive Drugs Market Attractiveness, by Therapy Type
7. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type
7.1. Introduction & Definition
7.2. Global Antihypertensive Drugs Market Value Forecast, by Type, 2017-2030
7.2.1. Primary Hypertension
7.2.2. Secondary Hypertension
7.3. Global Antihypertensive Drugs Market Attractiveness, by Type
8. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type
8.1. Introduction
8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2030
8.2.1. Monotherapy
8.2.2. Combination Therapy
8.2.3. Fixed Dose Combinations
8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type
9. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel
9.1. Introduction
9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2030
9.2.1. Retail Pharmacies
9.2.2. Hospital Pharmacies
9.2.3. Online Pharmacies
9.2.4. Others
9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel
10. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Region
10.1. Introduction
10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017-2030
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Antihypertensive Drugs Market Attractiveness, by Region
11. North America Antihypertensive Drugs Market Analysis and Forecast
11.1. Introduction
11.2. North America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2030
11.2.1. Diuretics
11.2.1.1. Thiazide diuretics
11.2.1.2. Loop diuretics
11.2.1.3. Potassium-sparing diuretics
11.2.2. Angiotensin Converting Enzyme Inhibitors
11.2.3. Angiotensin Receptor Blockers
11.2.4. Beta-blockers
11.2.4.1. Beta-1 Selective
11.2.4.2. Intrinsic Sympathomimetic
11.2.5. Vasodilators
11.2.6. Calcium Channel Blockers
11.2.7. Renin Inhibitors
11.2.8. Alpha-blockers
11.2.9. Others
11.3. North America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2030
11.3.1. Primary Hypertension
11.3.2. Secondary Hypertension
11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2030
11.4.1. Monotherapy
11.4.2. Combination Therapy
11.4.3. Fixed Dose Combinations
11.4.4. Others
11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2030
11.5.1. Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Online Pharmacies
11.5.4. Others
11.6. North America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2030
11.6.1. U.S.
11.6.2. Canada
11.7. North America Antihypertensive Drugs Market Attractiveness Analysis
11.7.1. By Therapy Type
11.7.2. By Type
11.7.3. By Medication Type
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe Antihypertensive Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Europe Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2030
12.2.1. Diuretics
12.2.1.1. Thiazide diuretics
12.2.1.2. Loop diuretics
12.2.1.3. Potassium-sparing diuretics
12.2.2. Angiotensin Converting Enzyme Inhibitors
12.2.3. Angiotensin Receptor Blockers
12.2.4. Beta-blockers
12.2.4.1. Beta-1 Selective
12.2.4.2. Intrinsic Sympathomimetic
12.2.5. Vasodilators
12.2.6. Calcium Channel Blockers
12.2.7. Renin Inhibitors
12.2.8. Alpha-blockers
12.2.9. Others
12.3. Europe Antihypertensive Drugs Market Value Forecast, by Type, 2017-2030
12.3.1. Primary Hypertension
12.3.2. Secondary Hypertension
12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2030
12.4.1. Monotherapy
12.4.2. Combination Therapy
12.4.3. Fixed Dose Combinations
12.4.4. Others
12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2030
12.5.1. Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Online Pharmacies
12.5.4. Others
12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2030
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis
12.7.1. By Therapy Type
12.7.2. By Type
12.7.3. By Medication Type
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2030
13.2.1. Diuretics
13.2.1.1. Thiazide diuretics
13.2.1.2. Loop diuretics
13.2.1.3. Potassium-sparing diuretics
13.2.2. Angiotensin Converting Enzyme Inhibitors
13.2.3. Angiotensin Receptor Blockers
13.2.4. Beta-blockers
13.2.4.1. Beta-1 Selective
13.2.4.2. Intrinsic Sympathomimetic
13.2.5. Vasodilators
13.2.6. Calcium Channel Blockers
13.2.7. Renin Inhibitors
13.2.8. Alpha-blockers
13.2.9. Others
13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Type, 2017-2030
13.3.1. Primary Hypertension
13.3.2. Secondary Hypertension
13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2030
13.4.1. Monotherapy
13.4.2. Combination Therapy
13.4.3. Fixed Dose Combinations
13.4.4. Others
13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2030
13.5.1. Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Online Pharmacies
13.5.4. Others
13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2030
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis
13.7.1. By Therapy Type
13.7.2. By Type
13.7.3. By Medication Type
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Antihypertensive Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2030
14.2.1. Diuretics
14.2.1.1. Thiazide diuretics
14.2.1.2. Loop diuretics
14.2.1.3. Potassium-sparing diuretics
14.2.2. Angiotensin Converting Enzyme Inhibitors
14.2.3. Angiotensin Receptor Blockers
14.2.4. Beta-blockers
14.2.4.1. Beta-1 Selective
14.2.4.2. Intrinsic Sympathomimetic
14.2.5. Vasodilators
14.2.6. Calcium Channel Blockers
14.2.7. Renin Inhibitors
14.2.8. Alpha-blockers
14.2.9. Others
14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2030
14.3.1. Primary Hypertension
14.3.2. Secondary Hypertension
14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2030
14.4.1. Monotherapy
14.4.2. Combination Therapy
14.4.2.1. Thiazide diuretics
14.4.2.2. Loop diuretics
14.4.2.3. Potassium-sparing diuretics
14.4.3. Angiotensin Converting Enzyme Inhibitors
14.4.4. Angiotensin Receptor Blockers
14.4.5. Beta-blockers
14.4.5.1. Beta-1 Selective
14.4.5.2. Intrinsic Sympathomimetic
14.4.6. Vasodilators
14.4.7. Calcium Channel Blockers
14.4.8. Renin Inhibitors
14.4.9. Alpha-blockers
14.4.10. Others
14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2030
14.5.1. Primary Hypertension
14.5.2. Secondary Hypertension
14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2030
14.6.1. Monotherapy
14.6.2. Combination Therapy
14.6.3. Fixed Dose Combinations
14.6.4. Others
14.7. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2030
14.7.1. Retail Pharmacies
14.7.2. Hospital Pharmacies
14.7.3. Online Pharmacies
14.7.4. Others
14.8. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2030
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of Latin America
14.9. Latin America Antihypertensive Drugs Market Attractiveness Analysis
14.9.1. By Therapy Type
14.9.2. By Type
14.9.3. By Medication Type
14.9.4. By Distribution Channel
14.9.5. By Country/Sub-region
15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2030
15.2.1. Diuretics
15.2.1.1. Thiazide diuretics
15.2.1.2. Loop diuretics
15.2.1.3. Potassium-sparing diuretics
15.2.2. Angiotensin Converting Enzyme Inhibitors
15.2.3. Angiotensin Receptor Blockers
15.2.4. Beta-blockers
15.2.4.1. Beta-1 Selective
15.2.4.2. Intrinsic Sympathomimetic
15.2.5. Vasodilators
15.2.6. Calcium Channel Blockers
15.2.7. Renin Inhibitors
15.2.8. Alpha-blockers
15.2.9. Others
15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Type, 2017-2030
15.3.1. Primary Hypertension
15.3.2. Secondary Hypertension
15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2030
15.4.1. Monotherapy
15.4.2. Combination Therapy
15.4.3. Fixed Dose Combinations
15.4.4. Others
15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2030
15.5.1. Retail Pharmacies
15.5.2. Hospital Pharmacies
15.5.3. Online Pharmacies
15.5.4. Others
15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2030
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Israel
15.6.4. Rest of Middle East & Africa
15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis
15.7.1. By Therapy Type
15.7.2. By Type
15.7.3. By Medication Type
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Company Profiles
16.2.1. Pfizer, Inc.
16.2.1.1. Company Description
16.2.1.2. Business Overview
16.2.1.3. Financial Overview
16.2.1.4. Strategic Overview
16.2.1.5. SWOT Analysis
16.2.2. Sanofi S.A
16.2.2.1. Company Description
16.2.2.2. Business Overview
16.2.2.3. Financial Overview
16.2.2.4. Strategic Overview
16.2.2.5. SWOT Analysis
16.2.3. Novartis AG
16.2.3.1. Company Description
16.2.3.2. Business Overview
16.2.3.3. Financial Overview
16.2.3.4. Strategic Overview
16.2.3.5. SWOT Analysis
16.2.4. Boehringer Ingelheim GmbH
16.2.4.1. Company Description
16.2.4.2. Business Overview
16.2.4.3. Financial Overview
16.2.4.4. Strategic Overview
16.2.4.5. SWOT Analysis
16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)
16.2.5.1. Company Description
16.2.5.2. Business Overview
16.2.5.3. Financial Overview
16.2.5.4. Strategic Overview
16.2.5.5. SWOT Analysis
16.2.6. F. Hoffmann-La Roche Ltd.
16.2.6.1. Company Description
16.2.6.2. Business Overview
16.2.6.3. Financial Overview
16.2.6.4. Strategic Overview
16.2.6.5. SWOT Analysis
16.2.7. Bayer AG
16.2.7.1. Company Description
16.2.7.2. Business Overview
16.2.7.3. Financial Overview
16.2.7.4. Strategic Overview
16.2.7.5. SWOT Analysis
16.2.8. Daiichi Sankyo Company, Limited
16.2.8.1. Company Description
16.2.8.2. Business Overview
16.2.8.3. Financial Overview
16.2.8.4. Strategic Overview
16.2.8.5. SWOT Analysis
16.2.9. Takeda Pharmaceutical Company Limited
16.2.9.1. Company Description
16.2.9.2. Business Overview
16.2.9.3. Financial Overview
16.2.9.4. Strategic Overview
16.2.9.5. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers